Barclays
WHWK

Barclays’s Whitehawk Therapeutics WHWK Stock Holding History

Barclays’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.5K Buy
6,433
+5,786
+894% +$24.1K ﹤0.01% 4499
2026
Q1 		$2.23K Buy
+647
New +$2.03K ﹤0.01% 4841
2024
Q3 		– Sell
-8
Closed -$11 – 5533
2024
Q2 		$11 Sell
8
-11,348
-100% -$21K ﹤0.01% 4789
2024
Q1 		$26.6K Sell
11,356
-10,905
-49% -$21K ﹤0.01% 4722
2023
Q4 		$45K Buy
22,261
+19,434
+687% +$81.5K ﹤0.01% 4790
2023
Q3 		$13.7K Sell
2,827
-401
-12% -$2.33K ﹤0.01% 4250
2023
Q2 		$22.1K Sell
3,228
-4,088
-56% -$31.8K ﹤0.01% 4117
2023
Q1 		$53K Buy
7,316
+3,428
+88% +$36.6K ﹤0.01% 4429
2022
Q4 		$49.9K Buy
3,888
+3,274
+533% +$42.7K ﹤0.01% 4553
2022
Q3 		$9K Sell
614
-326
-35% -$4.28K ﹤0.01% 4368
2022
Q2 		$12K Buy
+940
New +$14K ﹤0.01% 4581
2021
Q2 		– Sell
-777
Closed -$15K – 5118
2021
Q1 		$15K Buy
+777
New +$17.9K ﹤0.01% 4407

Other funds holding WHWK

YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's WHWK Position: Q2 2026 in Review

Barclays increased its Whitehawk Therapeutics (WHWK) stake by 894% in Q2 2026, buying an estimated $24.1K and bringing the position to 6,433 shares worth $29.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4499.

Barclays first reported a position in WHWK in Q1 2021 and has held it in 12 quarters since. The position peaked at $53K in Q1 2023. 77 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

  • Barclays held 6,433 shares of Whitehawk Therapeutics worth $29.5K as of Q2 2026.
  • Barclays bought 5,786 Whitehawk Therapeutics shares in Q2 2026, an estimated $24.1K.
  • Whitehawk Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4499 holding.
  • Barclays first reported a position in Whitehawk Therapeutics in Q1 2021 and has held it in 12 quarters since.
  • Barclays's Whitehawk Therapeutics position peaked at $53K in Q1 2023.
  • 77 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.